PharmiWeb Recruiter Blog

• Abbott will gain an innovative, complementary solution in treating vascular disease through CSI's leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow
• CSI's offering will support Abbott's ability to provide better care for patients with peripheral and coronary artery disease

ABBOTT PARK, Ill. and ST. PAUL, Minn., Feb. 8, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. Under terms of the agreement, CSI stockholders will receive $20 per common share at a total expected equity value of approximately $890 million.

For the eighth consecutive year, Advanced Clinical continues elite Diamond Award status

Chicago, IL (February 7, 2023) – Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, has earned the Best of Staffing® Client and Talent Awards by ClearlyRated for the eighth consecutive year and Diamond Award status for the fourth consecutive year.

• Study published today in Clinical Trials: Journal of the Society for Clinical Trials examined clinical trial diversity across 495 GSK trials involving over 100,000 participants
• Results demonstrate real-world disease epidemiology data—compared to the conventional standard of US Census data—may be better benchmark to ensure clinical trial enrolment reflects the populations affected by diseases
• GSK commits to applying insights from the study and collaborating with regulators, patients, academics and other biopharma companies to make meaningful progress on clinical trial diversity

GSK plc (LSE/NYSE: GSK) today announced results from a retrospective study on clinical trial diversity, investigating the historical representation of US-based participants in GSK clinical trials. The study looked at clinical trial demographic data from 495 GSK and ViiV clinical trials involving US-based participants from the period 2002 to 2019. The results published today in Clinical Trials: Journal of the Society of Clinical Trials demonstrate that using real world diseases epidemiology data, rather than the traditional benchmark of US Census Bureau race and ethnicity data, would ensure clinical trial enrolment reflects the populations affected by different diseases.

Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics

Thermo Fisher’s latest net-zero milestone to be achieved through 200-megawatt solar project

Both the US Skokie and European Rankweil sites address customer needs in early-phase drug development

• Clinical development pipeline is essential to global business strategy
• Vetter Development Service offers comprehensive expertise for in-human trial material
• New facility in Austria expands clinical manufacturing capacity

RAVENSBURG, Germany & RANKWEIL, Austria & SKOKIE, Ill.--(BUSINESS WIRE)--With the increasing drug development for novel therapeutics, a growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners to help meet the demand for complex fill and finish solutions. And, while the stages of early drug development are challenging, Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO) is committed to addressing this challenge by offering comprehensive expert manufacturing services for clinical trials and supporting their customer products path to commercialization. A testament to this commitment is evidenced by the success of its Skokie facility which has already contributed to bring five new customer products to market since it began full operations in 2011, with another four expected to launch in the next months.

Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients

Expansion of manufacturing facility in North Carolina will increase the number of patients who may benefit from the company's medicines

Charles River Edinburgh has been awarded Top Employer UK status for 2023. This internationally recognised award is given to organisations that show a passion and commitment to enriching the world of work for their employees. This is the second consecutive year that CRL EDI has received this award!

Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services